Redeye comments on the Q4 report released earlier this morning.
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sa...
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Kingspan bids SEK 182.5/shareNWG's board recommends accepting the bidHighly likely the bid will go t...
Redeye sees another strong quarter for OssDsign as sales beat our estimates with a continuing robust...
Raute reports Q4 results on Feb 13. FY’24 already showed strong results, while low valuation limits ...
Beat in Q4 driven by higher sales EBIT +7% vs ABGSCe Estimates likely to be revised up 2-5% on EBIT ...
Redeye is encouraged by the healthy rebound in demand witnessed in Ependion’s Q4 report.
Ahead of Taaleri's Q4 results, we revise our underlying estimates to reflect Taaleri's sale of its s...
DT reports Q4 results on Feb 6. We make limited estimate revisions ahead of the report as outlook re...
Dovre completed its segmental sale for a significant cash pile, the eventual use of which remains an...
SRV reports its Q4 figures on 6th of February. We expect slight improvement in adj.
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Redeye comments on the ongoing launch in Norway of Terclara.
